Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07222215 · ClinicalTrials.gov registry record · Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
A Phase 2 study of Breast Cancer and Metastatic Breast Cancer, sponsored by Kristina A. Fanucci.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 297
- Enrollment target
- 1
- Study location
NCT07222215: Recruiting Phase 2 study of Breast Cancer and Metastatic Breast Cancer, sponsored by Kristina A. Fanucci.
NCT07222215 is a Phase 2 study of Breast Cancer and Metastatic Breast Cancer that is actively recruiting participants, run by Kristina A. Fanucci. The registered enrollment target is 297 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07222215, a Phase 2 study of Breast Cancer and Metastatic Breast Cancer, is actively recruiting participants, sponsored by Kristina A. Fanucci.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 297 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer. This study is designed for participants with cancer that has previously stopped responding to medication in the class of therapy called CDK 4/6 inhibitors, including palbociclib, ribociclib, or abemaciclb. The names of the study drugs involved in this study are: * Elacestrant (a type of selective estrogen receptor degrader) * Capecitabine (a type of fluoropyrimidine antimetabolite)
Primary Outcome
PFS based on the Kaplan-Meier method is defined as the time from study randomization to disease progression per RECIST 1.1 or death. Patients alive without disease progression are censored at the date of last disease evaluation.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Elacestrant
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2026-01-16 |
| Est. Completion | 2030-10-01 |
| Phase | Phase 2 |
What NCT07222215 shows while recruiting
NCT07222215 is an interventional study that assigns participants to a tested intervention. The registered 297 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (89% lower).
The record links to 9 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Capecitabine is the first listed.
NCT07222215 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07222215 about?
NCT07222215 is a clinical study titled "PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)". The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer. This study is designed for participants with cancer that has previously stopped responding to medic...
What is the current status of trial NCT07222215?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 297 participants. The study started on 2026-01-16. Estimated completion is 2030-10-01.
What conditions does trial NCT07222215 study?
This clinical trial studies the following conditions: Breast Cancer, Metastatic Breast Cancer, Breast Neoplasms, Hormone Receptor-Positive Breast Cancer, Estrogen Receptor-positive Breast Cancer.
What interventions are being tested in trial NCT07222215?
The interventions under investigation include: Capecitabine (DRUG), Elacestrant (DRUG).
Who is sponsoring clinical trial NCT07222215?
This trial is sponsored by Kristina A. Fanucci, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07222215 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07222215's enrollment target sits among peer trials
297 290th of 1224 higher than 935 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
- NCT06375811 · 297 participants · Phase 3
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
- NCT06754215 · 298 participants · NA
Smoking Cessation Intervention Development for Homeless Youth
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI